An Open-labelled, Single Center, Comparative Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease
Phase of Trial: Phase I/II
Latest Information Update: 04 Oct 2016
At a glance
- Drugs Umbilical cord mesenchymal stem cell therapy-Kangstem Holdings (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kangstem Biotech
- 07 Jun 2017 Biomarkers information updated
- 27 Sep 2016 Planned End Date changed from 1 Apr 2016 to 1 Aug 2017.
- 27 Sep 2016 Planned primary completion date changed from 1 Dec 2015 to 1 May 2017.